Investigating FCGR2A and FCGR3A polymorphisms in this cohort were to determine whether variations in these IgG-binding receptors could influence ITP susceptibility and clinical presentation. This evidence concerns the gene FCGR3A and autoimmune thrombocytopenic purpura.